Search company, investor...

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Mirna Therapeutics

Mirna Therapeutics is a company focused on the development of microRNA based oncology therapies, operating within the biotechnology and healthcare industry. The company's main offerings include therapies for solid and hematologic cancers, utilizing microRNA technology. These therapies aim to treat cancer by replacing or modifying microRNAs, small molecules that regulate gene expression. It was founded in 2007 and is based in Austin, Texas.

Headquarters Location

2150 Woodward Street Suite 100

Austin, Texas, 78744,

United States




Mirna Therapeutics Patents

Mirna Therapeutics has filed 20 patents.

patents chart

Application Date

Grant Date


Related Topics




MicroRNA, RNA, RNA interference, Molecular biology


Application Date


Grant Date



Related Topics

MicroRNA, RNA, RNA interference, Molecular biology



Latest Mirna Therapeutics News

Precision Medicine's Secret Weapon: The Growing miRNA Tools and Services Market | CAGR of 19.3%

Nov 1, 2023

| CAGR of 19.3% News Provided By Share This Article The global mirna tools and services market size is projected to reach $1.8 billion by 2031, growing at a CAGR of 19.3% from 2022 to 2031. PORTLAND, OREGON, UNITED STATES, November 1, 2023 / / -- The miRNA Tools and Services Market is at the forefront of cutting-edge research and innovation in the field of molecular biology. This dynamic market offers a wide range of tools, technologies, and services that are instrumental in studying microRNAs, tiny yet influential molecules that play a crucial role in gene regulation. With applications in diagnostics, therapeutics, and biomarker discovery, miRNA tools and services are empowering scientists and researchers to delve deeper into the intricate world of genomics and gene expression, opening doors to new possibilities in personalized medicine and disease management. The global mirna tools and services market was valued at $311.86 million in 2021, and is projected to reach $1.8 billion by 2031, growing at a CAGR of 19.3% from 2022 to 2031. ๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‚๐จ๐ฉ๐ฒ ๐Ž๐Ÿ ๐“๐ก๐ข๐ฌ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ: One of the key players in the miRNA tools and services industry is Qiagen, a global leader in sample and assay technologies. Qiagen offers a range of miRNA products including miRNA isolation kits, miRNA quantification assays, and miRNA expression profiling arrays. The company also provides miRNA analysis services, such as miRNA sequencing and miRNA target prediction. Major market players covered in the report, such as - Agilent Technologies INC., Key Benefits for Stakeholders - โ€ข The report provides quantitative analysis of market segments, current trends, strategies and potential of MiRNA Tools and Services Market research to identify potential MiRNA Tools and Services Market opportunities in genetics. โ€ข In-depth analysis of this sector helps identify current market opportunities. โ€ข Market analysis and information related to key drivers, restraints and opportunities are provided. โ€ข Porter's Five Forces Analysis identifies the capabilities of buyers and suppliers to enable stakeholders to make profitable business decisions and strengthen the network of buyers. โ€ข The largest countries in each region are listed according to their contribution to the global market. โ€ข Focusing on market players makes benchmarking easier and provides a clear understanding of the current market situation. โ€ข The report includes regional and global MiRNA Tools and Services Market analysis, key players, market segments, application areas and Market growth strategies. In addition to these established companies, there are also many emerging miRNA tools and services providers, such as miRagen Therapeutics and miRNA Therapeutics. These companies are developing miRNA-based therapeutics for various diseases, including cancer and cardiovascular disease. The miRNA tools and services industry is expected to continue growing in the coming years, driven by the increasing demand for precision medicine and personalized therapies. With the advent of new technologies and approaches, such as single-cell sequencing and gene editing, the potential for miRNA-based therapies and diagnostics is immense. In conclusion, the miRNA tools and services industry is a vital component of the expanding field of precision medicine. These tools and services enable researchers and clinicians to gain a deeper understanding of miRNA biology and develop innovative therapies for a range of diseases. As the industry continues to grow, we can expect to see many more exciting advancements in the field of miRNA research and application. ๐…๐จ๐ซ ๐๐ฎ๐ซ๐œ๐ก๐š๐ฌ๐ž ๐„๐ง๐ช๐ฎ๐ข๐ซ๐ฒ - Q1. What is the total market value of MiRNA Tools and Services Market report? Q2. Which are the top companies holding the market share in MiRNA Tools and Services Market? Q3. Which are the largest regions for this Market? Q4. What is the leading technology of MiRNA Tools and Services Market? Q5. What are the major drivers for this specific Market? Q6. What are the upcoming key trends in the MiRNA Tools and Services Market report? About Us - Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. David Correa

Mirna Therapeutics Frequently Asked Questions (FAQ)

  • When was Mirna Therapeutics founded?

    Mirna Therapeutics was founded in 2007.

  • Where is Mirna Therapeutics's headquarters?

    Mirna Therapeutics's headquarters is located at 2150 Woodward Street, Austin.

  • What is Mirna Therapeutics's latest funding round?

    Mirna Therapeutics's latest funding round is IPO.

  • How much did Mirna Therapeutics raise?

    Mirna Therapeutics raised a total of $96.1M.

  • Who are the investors of Mirna Therapeutics?

    Investors of Mirna Therapeutics include New Enterprise Associates, Correlation Ventures, Sofinnova Ventures, Pfizer Venture Investments, Osage University Partners and 12 more.

  • Who are Mirna Therapeutics's competitors?

    Competitors of Mirna Therapeutics include NGM Biopharmaceuticals, Pique Therapeutics, Zymeworks, Cellerant Therapeutics, Immutep and 7 more.


Compare Mirna Therapeutics to Competitors

Carigent Therapeutics

Carigent Therapeutics is a biotechnology firm located in New Haven, CT dedicated to the development of next-generation therapeutic agents using a proprietary platform that is extremely versatile and robust.

Dialectica srl

Dialectica offers Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases. The mission of Dialectica is to add value to the link between research and pharmaceutical and biotechnology companies that are active in the discovery of therapeutics for brain diseases. Dialectica develops and optimize Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases.

Replikun Biotech

Replikun Biotech is a immunotherapy company founded in March 2005. The company is focused on the development and commercialization of immunotherapies to combat infectious diseases and cancer. Replikun offers licensing and collaboration opportunities based on KUNrep Vectors, its gene delivery and expression technology. The technology is underpinned by an integrated portfolio of granted and pending patent applications which comprise the KUNrep Vectors, their pharmaceutical applications and methods of manufacture. Replikun Biotech is conducting pre-clinical studies of two products: an investigational oncology candidate and a HIV vaccine, both developed using the KUNrep Vector system.


Spaltudaq is a company that specializes in the construction industry, with a focus on roofing services. The company offers a range of services including roof installation, roof replacement, and roof repair, catering to both residential and commercial needs. These services are designed to ensure the durability and longevity of roofing systems, providing protection and security for buildings. It was founded in 2004 and is based in Seattle, Washington.

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ฦ’ฦ’โ€šฦ’ลกโ€š" where it has achieved FDA orphan drug status ฦ’ฦ’โ€šฦ’ลกโ€š" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.


is a contract research organization that collaborates with R&D departments of biotechnology and biopharmaceutical companies to discover and develop new medicines. The company also engages in its own drug discovery agenda to develop treatments of treat tropical diseases such as malaria.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policyย here. By continuing to use this site you are consenting to these choices.